FRI0595 MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?
Authors: Emre Bilgin, Deniz Can Güven, Serdar Ceylan, Özge Aybi, Rıza Can Kardaş, Büşra Fırlatan, Tolga Yıldırım, Seza Özen, Ömer Dizdar, Kadir Mutlu Hayran, Umut Kalyoncu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Recent studies suggested that the cancer incidence may be lower among FMF patients compared with healthy controls. <h3>Objectives</h3> We have assessed cancer risk among FMF patients with or without amyloidosis to confirm this hypothesis. <h3>Methods</h3> We studied FMF patients, diagnosed and followed-up in Hacettepe University hospitals. Patients were identified from the hospital registry by using the ICD-10 code for FMF. Presence of amyloidosis was also noted. Data related to cancer were collected from patient files and oncology hospital registries. We calculated age- and gender-specific standardized incidence rates according to the Turkish National Cancer Registry data at 2014. <h3>Results</h3> Total of 3899 FMF patients (120 patients had also amyloidosis) were included. Median age was 22 and 56% were females. Thirty-eight (0.1%) patients had cancer during the study period. Type and distribution of cancers were as follow; females: 7 breast, 5 lymphoma, 4 ovarian, 2 renal, 2 central nervous system, 2 connective tissue sarcoma, 1 lung, 1 colorectal, 1 gastric, 1 endometrium, 1 leukemia and 1 yolk sac cancer; males: 2 leukemia, 1 prostate, 1 colorectal, 1 renal, 1 pancreas, 1 lymphoma, 1 Kaposi sarcoma and 2 unclassified adenocancer. The overall cancer risk among patients with FMF was significantly lower in both males (SIR 0.42 (95% CI 0.21-0.75), p=0.002) and females (SIR 065 (95% CI 0.44-0.93), p=0.019). The overall cancer risk among patients with FMF and amyloidosis was (SIR 1.21 (95% CI 0.49-2.52), p = 0.73) without gender difference. Although the overall cancer risk seems decreased, an increased risk was found among female patients under 20 years-old (SIR 3.44 (95% CI 1.26-7.64), p = 0.003), however, there was no predominant type of cancer in this group. Detailed SIR values according to sex and age groups are given in Table 1. <h3>Conclusion</h3> Cancer incidence was significantly lower in FMF patients, confirming the results of a previous study. However, we found an increased cancer risk among female patients under 20 years-old. Further prospective studies especially in this age group are needed to comfirm this association. If so, early cancer screening may be considered in this particular patient group. Additionally, we found no increased cancer risk in FMF patients having amyloidosis. Possible underlying mechanisms need to be explained. <h3>References</h3> <h3>Disclosure of Interests</h3> Emre Bilgin: None declared, Deniz Can Güven: None declared, Serdar Ceylan: None declared, Özge Aybi: None declared, Rıza Can Kardaş: None declared, Büşra Fırlatan: None declared, Tolga Yıldırım: None declared, Seza Özen Consultant for: Seza Ozen is receiving consultancy fees from Novartis, Speakers bureau: Roche, Ömer Dizdar: None declared, Kadir Mutlu Hayran: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim